NCT00977977View on ClinicalTrials.gov

Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

December 22, 2010

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
Nephrotic SyndromeProteinuriaAutoimmune DiseaseGlomerular DiseaseMembranous Glomerulonephritis
Interventions
DRUG

Rituximab Infusion

Drug Rituximab Infusion 2 infusions (each 1000 mg) separated by 2 weeks; repeated after 6 months

DRUG

Oral Cyclosporine

Daily therapy for 6 months (3-5 mg/kg), then tapered and discontinued

Trial Locations (2)

20889

RECRUITING

National Naval Medical Center, Bethesda

20892

RECRUITING

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

NCT00977977 - Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy | Biotech Hunter | Biotech Hunter